Received Jun 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | NT357 | — |
Diagnosed with Bell's Palsy after first Shingrix vaccine dose; This serious case was reported by a pharmacist via call center representative and described the occurrence of bell's palsy in a 71-year-old male patient who received Herpes zoster (Shingrix) solution for injection (batch number NT357 with expiry date 12-MAY-2028) for prophylaxis. On 30-APR-2026, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced bell's palsy (Verbatim: Diagnosed with Bell's Palsy after first Shingrix vaccine dose) (serious criteria GSK medically significant). The outcome of the bell's palsy was unknown. It was unknown if the reporter considered the bell's palsy to be related to Shingrix. The company considered the bell's palsy to be unrelated to Shingrix. Additional Information: GSK Receipt date: 11-JUN-2026 The pharmacist reported that the patient was diagnosed with bell's palsy after receiving the first Shingrix vaccine.; Sender's Comments: A case of Bell's palsy, on an unknown time after vaccination with 1st dose of Shingrix, in a 71-year-old male patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Further follow up information has been sought.